Amidst Market Carnage, HYAC Sets Vote Date for Biote

by | May 5, 2022

Bloodbath for the markets today. Biote next up for a vote. MAQC extends. And the rest of the day’s news in SPACs.

————————————————-
Free Investor Resources from Boardroom Alpha
—————————————————-
** Podcast: Know Who Drives Return
** Daily SPAC Newsletter
** Full SPAC Listing

Yesterday’s relief really did a sharp U-turn today, with the S&P500 falling a precipitous 3.5% and the Nasdaq 100 dropping 5%. Today was mostly a day to take cover and hide. Still, there was some activity in SPACland.

MAQC Extends Deadline

Maquia Capital Acquisition Corp. (MAQC) confirms using first extension to 8/7. Adds $0.10 to trust, bringing NAV to ~$10.25.

HYAC Sets Date for Biote Vote

Haymaker Acquisition Corp. III (HYAC): sets 5/24 date for merger vote on medical practice-building company Biote. Expected completion in the first half of 2022; company to be listed on the NASDAQ under the ticker symbol “BTMD.”

Elsewhere in SPACs

  • Extension meeting for Breeze Holdings Acquisition Corp. (BREZ) today. Proposed extension to 9/26.
  • Boardroom Alpha SPAC market review for April.

Upcoming Events

Source: Boardroom Alpha

More from Boardroom Alpha

For ongoing tracking, analytics, and data on SPACs checkout Boardroom Alpha’s SPAC Data and Analytics service.

Recent Analysis

Daily SPAC Update – Feb 20, 2024

DWAC Sets Deal Vote. CMCA, CFFS, BNIX Extension Votes Set. Deal Deck for LBBB. GIA + QT Imaging Deal Vote. ACAC Announces Deal with Foxx Development.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.